NPM2 表达缺失是恶性腹膜间皮瘤的潜在免疫组织化学标志物：一项 92 例的单中心研究。
Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.
机构信息
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Peking University Ninth School of Clinical Medicine, Beijing, 100038, China.
Department of Peritoneal Cancer Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
出版信息
World J Surg Oncol. 2022 Oct 24;20(1):350. doi: 10.1186/s12957-022-02811-y.
BACKGROUND
Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecular chaperone that binds histones and may play a key role in the development and progression of tumors. This study aimed to analyze the correlation between the expression level of NPM2 and the main clinicopathological characteristics and prognosis of MPM.
METHODS
Ninety-two postoperative specimens from MPM patients following cytoreductive surgery were collected. Postoperative specimens were stained with immunohistochemistry. The expression level of NPM2 was quantitatively analyzed by QuPath-0.3.2 software. Univariate and multivariate analyses were conducted to investigate the correlation between NPM2 expression and other conventional clinicopathological characteristics.
RESULTS
Among the 92 MPM patients, there were 47 males (48.9%) and 45 females (51.1%), with a median age of 56 (range: 24-73). There were 70 (76.0%) cases with loss of NPM2 protein expression, 11 (12.0%) cases with low expression, and 11 (12.0%) cases with high expression. Univariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was negatively correlated with the following three clinicopathological factors: completeness of cytoreduction (CC) score, vascular tumor emboli, and serious adverse events (SAEs) (all P < 0.05). Multivariate analysis showed that NPM2 protein expression level (negative vs. low expression vs. high expression) was independently negatively correlated with the following two clinicopathological factors: CC score [odds ratio (OR) = 0.317, 95% CI: 0.317-0.959, P = 0.042] and vascular tumor emboli (OR = 0.092, 95% CI = 0.011-0.770, P = 0.028). Survival analysis showed that loss of NPM2 protein expression (negative vs. positive) was associated with poor prognosis of MPM.
CONCLUSIONS
Loss of NPM2 expression is a potential immunohistochemical marker for MPM.
背景
恶性腹膜间皮瘤（MPM）是一种罕见的恶性肿瘤，死亡率高，预后极差。深入的病理分析对于评估肿瘤的生物学行为和探索 MPM 的潜在治疗靶点至关重要。核蛋白 2（NPM2）是一种分子伴侣，它与组蛋白结合，可能在肿瘤的发生和发展中起关键作用。本研究旨在分析 NPM2 的表达水平与 MPM 的主要临床病理特征和预后之间的相关性。
方法
收集 92 例接受细胞减灭术后的 MPM 患者的术后标本。术后标本用免疫组织化学染色。采用 QuPath-0.3.2 软件对 NPM2 的表达水平进行定量分析。通过单因素和多因素分析，探讨 NPM2 表达与其他常规临床病理特征之间的相关性。
结果
92 例 MPM 患者中，男 47 例（48.9%），女 45 例（51.1%），中位年龄 56 岁（范围：24-73 岁）。70 例（76.0%）患者存在 NPM2 蛋白表达缺失，11 例（12.0%）为低表达，11 例（12.0%）为高表达。单因素分析显示，NPM2 蛋白表达水平（阴性与低表达与高表达）与以下三个临床病理因素呈负相关：肿瘤细胞减灭术（CC）评分、血管肿瘤栓子和严重不良事件（SAEs）（均 P<0.05）。多因素分析显示，NPM2 蛋白表达水平（阴性与低表达与高表达）与以下两个临床病理因素呈独立负相关：CC 评分[比值比（OR）=0.317，95%可信区间（CI）：0.317-0.959，P=0.042]和血管肿瘤栓子（OR=0.092，95%CI=0.011-0.770，P=0.028）。生存分析显示，NPM2 蛋白表达缺失（阴性与阳性）与 MPM 的预后不良相关。
结论
NPM2 表达缺失是 MPM 的一种潜在免疫组织化学标志物。
Zotero 插件